As a leading company in the field of anti-infective drugs, we will expand and improve our lineup, covering vaccines for prevention through to antibacterial drugs. At the same time, we will not only develop new drugs but also provide biopharmaceuticals and high-quality generic drugs in Japan and overseas. In a wide range of disease fields, we will contribute to the progress of drug treatments and the realization of appropriate drug prices.

Also, as we develop our businesses, we will contribute to social issues by preparing for the threat of infectious diseases, enhancing access to pharmaceuticals, and improving productivity in the agricultural industry by providing environment-friendly agricultural chemicals and veterinary drugs.

Given that we are engaged in industries that affect life, each of our employees is dedicated to working sincerely day in and day out.

We will “make life lively” through pharmaceuticals that can support the lives of people worldwide.

The Meiji Group’s System of Principles

**Group Philosophy**

Our mission is to widen the world of “Tastiness and Enjoyment” and meet all expectations regarding “Health and Reassurance.”

Our wish is to be closely in tune with our customers’ feelings and to always be there to brighten their daily lives.

Our responsibility as “Food and Health” professionals is to continue finding innovative ways to meet our customers’ needs, today and tomorrow.

**Management Attitude**

**Five Fundamentals**

1. Commit ourselves to customer-based ideas and behaviors
2. Provide safe and reassuring high-quality products
3. Strive to always produce new value
4. Foster the development of the synergies and capabilities of the organization and each individual
5. Be a transparent, wholesome company trusted by society

**Action Guidelines**

**meiji way**

In order to be an essential part of our customers, partners, and colleagues’ daily lives, we must:

1. Listen to and learn from our customers
2. Find ways to identify tomorrow’s trends and be prepared to lead the way
3. Make our work exciting, and create exciting work
4. Have the strength and courage to confront any issues, rather than to avoid them
5. Always believe in our team’s potential, and make the most of its abilities

Daikichiro Kobayashi
President and Representative Director
Meiji Seika Pharma Co., Ltd.
Japan

76%

Net sales

¥171.691 billion
(Consolidated sales for the FYE March 2019)

Overseas

24%

Number of Employees

5,759
(As of March 31, 2019)

Japan

76%

Sales ratio

Overseas

24%

Meiji Holdings Co., Ltd.

Meiji Co., Ltd.

Meiji Seika Pharma Co., Ltd.

KM Biologics Co., Ltd.

The Meiji Group 2026 Vision Beyond meiji - above imagination -

Our promise and commitment for the 2026 Vision

We will combine the strengths, the Meiji Group has cultivated over the past 100 years, with the latest technology and new findings. Thus we create innovative ways to meet our customers’ needs with food and health and grow in Japan and around the world sustainably.

Goals

Operating income growth rate
Mid to high single-digit growth (CAGR*)

Overseas sales ratio
Target at 20%

ROE
Maintain 10% or more

Key Strategies

1 Secure an overwhelming advantage in core businesses
2 Establish growth foundation in overseas markets
3 New challenges in the health value domain
4 Social contributions

Beyond meiji the 1st stage Medium-Term Business Plan (FYE March 2019-2021)

Basic concept

Address strategic issues continuously and challenge for the further growth

Goals (JPY)

Net Sales

1,350 billion

Operating Income (OPM)

125 billion (9.3%)

Overseas Sales

142 billion

ROE

13% range

* CAGR: Compound annual growth rate (%)

2020 Medium-Term Business Plan
(FYE March 2019–2021)

2023 Medium-Term Business Plan
(FYE March 2022–2024)

2026 Medium-Term Business Plan
(FYE March 2025–2027)
Infectious Diseases Field

After beginning penicillin production in 1946, we launched STREPTOMYCIN MEIJI for tuberculosis treatment in 1950 and Japan’s first internationally viable drug, KANAMYCIN MEIJI, in 1958. As Japan’s top manufacturer of antibacterial drugs, we offer an extensive lineup of drugs for infectious diseases. In 1990, we launched HABEKACIN, the first MRSA infection treatment in Japan. In 1994, we launched MEIACT, an oral cephalosporin antibiotic. In 2009, we launched ORAPENEM, the world’s only oral carbapenem antibacterial drug for pediatric use.

Also, we have launched a range of antibacterial generic drugs, including SULBACILLIN, VANCOMYCIN MEEK, and TAZOPIPE MEIJI. We have established the leading share of Japan’s systemic antibacterial drugs market.

In addition, we have begun selling human vaccines developed and produced by KM Biologics Co., Ltd., which joined the Meiji Group in 2018. These include Influenza HA Vaccine “KMB” and the DTaP-IPV vaccine Quattrovac.

As the importance of and demand for vaccines grows worldwide, we will contribute to infectious disease prevention and public health enhancement by providing both vaccine products and our specialty anti-infective drugs.

CNS Disorders Field

Central nervous system (CNS) disorders continue to increase for a range of reasons, such as the aging of society in Japan, changing lifestyles, and stress. In response to these medical needs, we have provided a wide variety of evidence-based drugs mainly in the mood disorder field. In the CNS disorders field, we launched the antianxiety drug MEILAX in 1989; Japan’s first selective serotonin reuptake inhibitor (SSRI), DEPROMEL, in 1999; and Japan’s first noradrenergic and specific serotonergic antidepressant (NaSSA), REFLEX, in 2009. Further, current efforts to increase our presence in the schizophrenia field are focused on SYCREST launched in 2016. We will continue taking on the challenge of providing groundbreaking antidepressant drugs and schizophrenia drugs.

Ethical Pharmaceuticals Business

We have been providing a range of pharmaceuticals for over 70 years, since the pharmaceutical business segment of Meiji Seika Kaisha, Ltd., our predecessor, began producing penicillin in 1946. We will continue supporting people’s health and lives as a “Speciality & Generic Pharmaceutical Company” that is focused on its core domains of infectious diseases and central nervous system disorders and which also provides high-quality generic drugs.
Peripheral and Other Fields

In fields peripheral to its mainstay fields of infectious diseases and CNS disorders, the brand-name drug business offers such drugs as the anti-allergy drug BILANO, the chronic obstructive and pulmonary disease (COPD) drugs ULITBRO and SEE, and the anticancer drugs THERARUBICIN and LASERPHYRIN. Also, we market drugs, medical devices, and medical materials in the health management field, including products for prevention and prognosis. In 2018, we launched EPISIL ORAL LIQUID. We will cater to a variety of medical needs by expanding and improving this product lineup.

As a “Speciality & Generic Pharmaceutical Company”

Meiji Seika Pharma has led other brand-name drug companies in developing a generic drug business as a “Speciality & Generic Pharmaceutical Company.”

Focusing on its mainstays fields of infectious diseases and CNS disorders, the brand-name drug business is strengthening its product pipeline. As well as providing convenient high-quality generic drugs, we work to ensure information provision and stable supplies. In 2015, Medreich Limited of India joined the Meiji Group. Further, we established Me Pharma Co., Ltd., which sells products that Medreich manufactures for Japan’s domestic market.

We aim to economically provide stable supplies of high-quality generic drugs, which will mainly cater to the expected growth in demand for generic drugs for lifestyle related diseases and digestive diseases as Japan becomes a super-aging society.

Our Medical Representative Activities

Providing and Collecting High-Quality Information throughout Japan

At Meiji Seika Pharma, medical representatives (MRs) are assigned to university hospitals, local hospitals, and clinics in each region of Japan. MRs are responsible for promoting the use of our Company’s ethical pharmaceutical products, and some MRs are dedicated to promoting the use of CNS drugs in specialized diagnostic and treatment departments, such as in psychiatric and psychosomatic departments of hospitals and mental health clinics. Our MRs work closely with medical staff and patients in both providing and collecting information.

We have built a MR information provision support system and a pharmaceutical information search database for MR promotion activities in each region throughout Japan. Under this system, MRs can use digital tools to provide and obtain required information in a timely manner.
Agricultural Chemicals and Veterinary Drugs Business

Meiji Seika Pharma’s agricultural chemicals and veterinary drugs businesses contribute to supply stability, productivity and safety for agricultural, livestock, and marine products, supporting people’s lives worldwide.

Agricultural Chemicals

We began the agricultural chemicals business by launching the GIBBERELLIN plant growth regulator in 1961. Subsequently, we added the bactericide STREPTOMYCIN and the rice blast preventative ORYZEMATE to expand the business. Launched more than 40 years ago, ORYZEMATE remains Japan’s best-selling rice paddy agricultural chemical. Since 2011, we have expanded the business through the addition of the non-selective herbicide ZAXA, the paddy fungicide TRY, and the insecticide FINESAVE.

Also, we are actively out-licensing to major overseas agrochemical companies. We have out-licensed the insecticide afidopyropen to BASF and the fungicide fenpicoxamid to Dow AgroSciences (now DowDuPont Inc.). Both agricultural chemicals were produced by mobilizing our drug discovery technologies that use microorganisms. In 2018, we developed the paddy insecticide flupyrimin in India and licensed the sales rights to Arysta LifeScience Corporation. Each of these agricultural chemicals has a low environmental impact, and is expected to spread worldwide.

We will continue discovering groundbreaking new chemicals and contributing to the stable production of food worldwide.

Veterinary Drugs

In our veterinary drugs business, we are creating a product lineup to meet diverse needs. We have widened our activities by entering related areas, such as disinfectants and functional materials. In particular, we lead the industry in the fields of antibacterial drugs and disinfectants. Further, in the companion animals (CA) field, we contribute to veterinary treatments through anaesthetic and analgesic drugs and antiparasitic drugs.

Also, under the “One Health” initiative we are focusing on the importance of giving attention to animals and the environment to protect human health. We are working to heighten awareness of the appropriate use of drugs and developing new drugs that can contribute to this initiative.

We will strengthen the product lineup of the veterinary drugs business for the livestock and fisheries industries. At the same time, we will set our sights on using our expertise in vaccine development and feeding management to step up business development overseas.
Expanding Overseas Business, Especially in Asian Growth Markets

We began exporting an antibacterial drug in 1950, and currently ship meiji brand pharmaceuticals, including MEIACT and FOSMICIN, overseas.

Currently, we use a global production and sales network that is based on local subsidiaries in Indonesia, Thailand, China, Spain, and India to develop the ethical pharmaceuticals and veterinary drugs businesses and contribute to medicine and the livestock industry in countries around the world.

In 2015, Medreich Limited of India joined the Meiji Group. The company has an extensive track record in the CMO and CDMO businesses and large-scale production facilities. Medreich is catering to the steadily increasing worldwide demand for the contract manufacturing of pharmaceuticals.

Further, in 2017 the company began supplying Japan’s market with the high-quality generic drugs that it economically manufactures based on technical guidance and quality control methods from Japan.

Meiji Seika Pharma aims to be a corporate group that supports people’s lives worldwide through the development of its businesses overseas.
The R&D departments of Meiji Seika Pharma comprise its head office organization and four laboratories. These laboratories conduct R&D with the objective of becoming a speciality pharmaceutical company in the field of infectious diseases and CNS disorders. They also conduct R&D focused on generic drugs, agricultural chemicals, and veterinary drugs. We aim to incorporate new technologies and expertise into pharmaceutical R&D, create progressive value, and continue our growth in Japan and worldwide.

<table>
<thead>
<tr>
<th>Research and Development</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pharmaceutical Research Center</strong></td>
</tr>
<tr>
<td><strong>Chemistry, Manufacturing &amp; Control Research Labs</strong></td>
</tr>
<tr>
<td><strong>Bioscience Labs</strong></td>
</tr>
<tr>
<td><strong>Agricultural &amp; Veterinary Research Labs</strong></td>
</tr>
<tr>
<td><strong>Pharmaceutical Research &amp; Development Division</strong></td>
</tr>
</tbody>
</table>
Production

Our manufacturing of ethical pharmaceuticals is strictly controlled. We employ a quality control system based on good manufacturing practice (GMP) standards that covers the procurement of bulk drugs and raw materials, manufacturing, packaging, and shipping. We undertake integrated management of supply chains—from the procurement of raw materials through to product distribution—and we have established systems that can provide stable supplies.

The Company’s pharmaceutical plants have computerized manufacturing control systems. In addition, we rigorously enforce 5S (sorting, setting in order, systematic cleaning, standardizing, sustaining discipline) activities so that our manufacturing environments are always safe and ultra-clean.

In the same way that we do for ethical pharmaceuticals, for veterinary drugs and agricultural chemicals we stably supply customers with products of reliable quality.

Through strict control systems, stringent production control, and each employee’s strong commitment to quality, we deliver products of reliable quality to medical care facilities.

Reliability & Quality Assurance

Pharmaceuticals and medical devices, which affect people’s health and lives, are subject to strict standards, covering development and production through to shipping, collection of information on side effects, and provision of information on appropriate usage methods.

Meiji Seika Pharma’s Reliability Assurance Policy states: “We will contribute to society by earning the trust of patients and healthcare professionals.” In accordance with this policy, we have built a quality management system, and we are taking measures to ensure reliability and improve it even further. In addition, we conduct reliability assurance activities that encompass raw material procurement and collection of information about side effects, and other areas. These activities enable us to provide patients and healthcare professionals with high-quality products.
The Meiji Group’s Approach to CSR

The Meiji Group’s goal is to achieve a sustainable society for people to live healthy, peaceful lives.

We set up three themes: Healthier Lives, Caring for the Earth and A Richer Society. We established specific areas of activities under each theme. Based on this framework, shown in the figure, we promote CSR activities that are developed in the Meiji way. As Food and Health professionals, we will contribute to addressing social issues through our business activities.

Operating Bases and Group Companies

**Japan**
- Head Office
- Branches
  - [Pharmaceuticals]
    - Hokkaido
    - Sendai
    - Tokyo
    - Chiba & Saitama
    - Yokohama
    - Kanto
    - Nagoya
    - Kyoto
    - Osaka
    - Chugoku
    - Shikoku
    - Fukuoka
- [Agricultural Chemicals]
  - East
  - West
- Research Laboratories
  - Pharmaceutical Research Center
  - Chemistry, Manufacturing & Control Research Labs
  - Bioscience Labs
  - Agricultural & Veterinary Research Labs
- Plants
  - Odawara
  - Gifu
- Group Companies
  - Me Pharma Co., Ltd.
  - Kitasato Pharmaceutical Industry Co., Ltd.
  - OHKURA Pharmaceutical Co., Ltd.
  - MIYAKO YUSO TRANSPORTATION CO., LTD.

**Worldwide Locations**
- Offices
  - Beijing Office (China)
  - US Office (USA)
- Group Companies
  - Medreich Life care Limited (India)
  - Medreich plc (United Kingdom)
  - Medreich Australia Pty Ltd. (Australia)
  - Pharmazen Medicals Pte Ltd. (Singapore)
  - Medreich Far East Limited (Hong Kong)
  - Inopharm Limited (Cyprus)
  - Medreich New Zealand Limited (New Zealand)
  - Tedec Meiji Farma SA (Spain)
  - Meiji Seika Europe B.V. (Netherlands)
### The Group History

<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1916</td>
<td>Tokyo Confectionery Co., Ltd. (Tokyo Confectionery), the predecessor of Meiji Seika, is established.</td>
</tr>
<tr>
<td>1924</td>
<td>Tokyo Confectionery changes its name to Meiji Seika Kaisha, Ltd. (Meiji Seika).</td>
</tr>
<tr>
<td>1946</td>
<td>The pharmaceutical business is launched with the commencement of penicillin production.</td>
</tr>
<tr>
<td>1955</td>
<td>The veterinary penicillin-based feed additive MEIRICH P is launched. Meiji Seika enters the veterinary drugs business.</td>
</tr>
<tr>
<td>1961</td>
<td>The plant growth regulator GIBBERELLIN is launched. Meiji Seika enters the agricultural chemicals business.</td>
</tr>
<tr>
<td>1971</td>
<td>Operation of the Gifu Plant is commenced.</td>
</tr>
<tr>
<td>1974</td>
<td>The pharmaceutical business establishes PT. Meiji Indonesian Pharmaceutical Industries.</td>
</tr>
<tr>
<td>1976</td>
<td>Operation of the Kitakami Plant is commenced.</td>
</tr>
<tr>
<td>1979</td>
<td>The pharmaceutical business establishes Thai Meiji Pharmaceutical Co., Ltd.</td>
</tr>
<tr>
<td>1981</td>
<td>The antibiotic PANIMYCIN is launched.</td>
</tr>
<tr>
<td>1987</td>
<td>The antibiotic MEICELIN is launched.</td>
</tr>
<tr>
<td>1988</td>
<td>The anticancer drug THERARUBICIN is launched.</td>
</tr>
<tr>
<td>1989</td>
<td>The antianxiety drug MEILAX is launched. Kamei Pharmaceuticals (currently Shantou SEZ Meiji Pharmaceutical Co., Ltd.) is established in China. The Odawara Plant commences production operations as a pharmaceuticals plant.</td>
</tr>
<tr>
<td>1990</td>
<td>Meiji Seika launches Japan’s first treatment for Methicillin-resistant Staphylococcus Aureus (MRSA) infections, the antibiotic HABEKACIN.</td>
</tr>
<tr>
<td>1991</td>
<td>Enters into capital participation in Tedec Zambeletti (currently Tedec Meiji Farma SA) of Spain.</td>
</tr>
<tr>
<td>1994</td>
<td>The antibiotic MEIACT is launched.</td>
</tr>
<tr>
<td>1995</td>
<td>The hyaluronic acid injection for arthritis ADANT is launched.</td>
</tr>
<tr>
<td>1998</td>
<td>Generic Development Department is established and full-fledged entry to the generic drug market is commenced.</td>
</tr>
<tr>
<td>1999</td>
<td>The antidepressant DEPROMEL is launched.</td>
</tr>
<tr>
<td>2002</td>
<td>Operations of the Microbiological Research Center (currently Bioscience Labs.) are commenced.</td>
</tr>
<tr>
<td>2004</td>
<td>The photosensitizing agent LASERPHYRIN is launched.</td>
</tr>
<tr>
<td>2008</td>
<td>Meiji Seika launches the calcium channel blocker generic drug AMLODIPINE TABLETS MEIJI.</td>
</tr>
<tr>
<td>2009</td>
<td>Meiji Seika and Meiji Dairies establish Meiji Holdings Co., Ltd. (Meiji Holdings), joint holding company, and integrate the management.</td>
</tr>
<tr>
<td>2010</td>
<td>The antibiotic ORAPENEM and the antidepressant drug REFLEX are launched.</td>
</tr>
<tr>
<td>2011</td>
<td>OHKURA Pharmaceutical Co., Ltd. is transferred from Meiji Dairies Corporation.</td>
</tr>
<tr>
<td>2012</td>
<td>Treatment for COPD (Chronic Obstructive Pulmonary Disease) OXIS is launched.</td>
</tr>
<tr>
<td>2013</td>
<td>Treatment for Dravet syndrome DIACOMIT is launched.</td>
</tr>
<tr>
<td>2015</td>
<td>Medreich Limited of India joins the Group.</td>
</tr>
<tr>
<td>2016</td>
<td>Treatment for schizophrenia SYCREST is launched.</td>
</tr>
<tr>
<td>2017</td>
<td>Me Pharma Co., Ltd. starts operations.</td>
</tr>
<tr>
<td>2018</td>
<td>Influenza HA Vaccine “KMB” is launched.</td>
</tr>
</tbody>
</table>

*ISODINE® is a registered trademark of Mundipharma K.K.*

---

### Corporate Data

#### Trade Name
Meiji Seika Pharma Co., Ltd.

#### Main Businesses
Manufacturing and sale of ethical pharmaceuticals, agricultural chemicals and veterinary drugs

#### President and Representative Director
Daikichiro Kobayashi

#### Established
October 9, 1916

#### <Reference> Meiji Group Annual Sales
¥1,254.380 billion (FYE March 2019)

#### Number of Meiji Group Employees
17,608 (As of March 31, 2019)